BioCardia Announces Participation at H.C. Wainwright Global Investment Conference September 12-14, 2022 (HYBRID CONFERENCE)

Rhea-AI Summary

BioCardia, Inc. (NASDAQ: BCDA) announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022, at the Lotte New York Palace Hotel. Dr. Peter Altman, CEO, will present an overview of the company's business.
The firm focuses on developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, boasting two key products: CardiAMP® autologous and NK1R+ allogeneic cell therapies, with significant FDA designations and CMS reimbursements.

Positive

• Participation in a significant investment conference may enhance visibility and investor interest.
• CEO's presentation could lead to potential partnerships and investments.
• Breakthrough designation for CardiAMP Cell Therapy indicates strong FDA support.

Negative

• None.

SUNNYVALE, Calif., Sept. 09, 2022 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ, BCDA), today announced it will be featured as a presenting company at the H.C. Wainwright 24th Annual Global Investment Conference.  The conference is being held on September 12-14, 2022. The in-person venue for the event is the Lotte New York Palace Hotel in New York City located at 455 Madison Avenue. Virtual participation will be staged simultaneously with over 500 company presentations scheduled as live feed or available on-demand.

Dr. Peter Altman, CEO of BioCardia, will provide an overview of the Company's business during the presentation.

If you are an institutional investor, and would like to listen to the Company’s presentation, please visit www.hcwevents.com/annualconference to register for the conference.

About BioCardia

BioCardia, Inc., headquartered in Sunnyvale, California, is developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and NK1R+ allogeneic cell therapies are the Company’s biotherapeutic platforms that enable four product candidates in development. The CardiAMP Cell Therapy Heart Failure Trial investigational product has been granted Breakthrough designation by the FDA, has CMS reimbursement, and is supported financially by the Maryland Stem Cell Research Fund. The CardiAMP Chronic Myocardial Ischemia Trial also has CMS Reimbursement.   BioCardia also partners with other biotherapeutic companies to provide its delivery systems. For more information visit: www.BioCardia.com.

Media Contact:
Anne Laluc, Marketing
Email: alaluc@BioCardia.com
Phone: 650-226-0120

Investor Contact:
David McClung, Chief Financial Officer
Email: investors@BioCardia.com
Phone: 650-226-0120

FAQ

What is the significance of BioCardia's participation in the H.C. Wainwright 24th Annual Global Investment Conference?

BioCardia's participation enhances its visibility among institutional investors, potentially attracting new investments.

Who will represent BioCardia at the investment conference?

Dr. Peter Altman, the CEO of BioCardia, will represent the company by providing an overview of its business.

What are the key products developed by BioCardia?

BioCardia develops Cellular and cell-derived therapeutics, with key products including CardiAMP autologous and NK1R+ allogeneic cell therapies.

What regulatory support does BioCardia's CardiAMP Cell Therapy have?

The CardiAMP Cell Therapy has received Breakthrough designation from the FDA and CMS reimbursement support.